Get the Stockscreener App
28.87
2.56%
0.72
After Hours:
29.00
0.13
+0.45%
Alumis Inc stock is traded at $28.87, with a volume of 989.03K.
It is up +2.56% in the last 24 hours and up +9.56% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
See More
Previous Close:
$28.15
Open:
$28.41
24h Volume:
989.03K
Relative Volume:
0.36
Market Cap:
$3.60B
Revenue:
$22.12M
Net Income/Loss:
$-245.15M
P/E Ratio:
-7.4898
EPS:
-3.8546
Net Cash Flow:
$-373.40M
1W Performance:
-1.77%
1M Performance:
+9.56%
6M Performance:
+527.61%
1Y Performance:
+528.98%
1-Day Range:
$28.19
$29.39
1-Week Range:
$27.73
$30.06
52-Week Range:
$2.7601
$30.60
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
28.87 | 3.51B | 22.12M | -245.15M | -373.40M | -3.8546 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-21-26 | Initiated | Chardan Capital Markets | Buy |
| Jul-25-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Resumed | Guggenheim | Buy |
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
Phase III wins lift Alumis, Corcept shares in January - bioworld.com
Alumis to Present at the Leerink Partners Global Healthcare Conference - The Manila Times
ALMS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ALMS Stock Price, Quote & Chart | ALUMIS INC (NASDAQ:ALMS) - ChartMill
Alumis Inc. (NASDAQ:ALMS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference - Yahoo Finance
ALMS SEC FilingsAlumis Inc 10-K, 10-Q, 8-K Forms - Stock Titan
This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Alumis Inc. (ALMS) Investor Outlook: Analyzing a Potential 29% Upside in Biotech Innovation - DirectorsTalk Interviews
Aug Retail: Is Alumis Inc gaining market sharePortfolio Return Summary & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
ALMS Should I Buy - Intellectia AI
This Oracle Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Stifel Nicolaus Initiates Coverage on Alumis (NASDAQ:ALMS) - MarketBeat
Stifel Initiates Alumis at Buy With $44 Price Target - marketscreener.com
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Stifel initiates Alumis stock with buy rating on TYK2 potential - Investing.com Australia
Stifel initiates Alumis stock with buy rating on TYK2 potential By Investing.com - Investing.com Canada
ALMS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Alumis Inc. (ALMS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
A | What is Alumis Inc.'s debt-to-equity ratio2025 Macro Impact & Fast Moving Trade Plans - mfd.ru
Big Picture: Is Alumis Inc in a consolidation phaseWeekly Trend Report & Long-Term Growth Plans - baoquankhu1.vn
Alumis Inc stock hits all-time high at 28.34 USD By Investing.com - Investing.com India
Alumis Inc stock hits all-time high at 28.34 USD - Investing.com Nigeria
Alumis (NASDAQ:ALMS) Sets New 52-Week HighStill a Buy? - MarketBeat
Risk Hedge: Is Alumis Inc gaining market shareJuly 2025 Retail & Technical Pattern Based Buy Signals - baoquankhu1.vn
Huge insider buying now at this insurance giant and 2 biotechs - MSN
Alumis Stock: Key Catalysts on the Horizon for 2026 - AD HOC NEWS
Credit Industriel ET Commercial Sells 140,000 Shares of Alumis Inc. $ALMS - MarketBeat
Why Alumis Inc. stock is trending among retail tradersProduct Launch & Weekly Watchlist for Hot Stocks - mfd.ru
Can Alumis Inc. expand into new markets2025 Momentum Check & Short-Term Swing Trade Alerts - mfd.ru
Alumis (NASDAQ:ALMS) Shares Up 7.2%Still a Buy? - MarketBeat
Alumis Highlights Phase III Psoriasis Wins, NDA Timing, and Lupus Catalyst at Guggenheim Summit - MarketBeat
Alumis Inc. (ALMS) Investor Outlook: Biotech Innovator With A 45% Upside Potential - DirectorsTalk Interviews
Is Alumis Inc.’s growth already priced inPortfolio Growth Summary & Weekly Watchlist of Top Performers - mfd.ru
Quarterly Risk: Is Alumis Inc in a consolidation phase2025 Price Action Summary & Growth Focused Entry Reports - baoquankhu1.vn
Can Alumis Inc. ride the EV wave2025 Pullback Review & Weekly High Potential Stock Alerts - mfd.ru
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter. - AOL.com
Alumis (ALMS) Valuation Check After Strong Multi‑Month Share Price Momentum - Yahoo Finance
Alumis Ownership Shifts As Shelf Filing And Conferences Shape Outlook - Sahm
EPS Watch: Can Alumis Inc ride the EV waveWeekly Stock Analysis & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Market Leaders: Will TWFG outperform the market in YEARTrade Analysis Report & High Win Rate Trade Alerts - baoquankhu1.vn
Alumis to Participate in Upcoming February Investor Conferences - The Manila Times
Biotech firm Alumis lines up two February investor webcasts - Stock Titan
Alumis Inc. (NASDAQ:ALMS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Alumis and ACELYRIN announce merger in all-stock deal - MSN
Alumis (NASDAQ:ALMS) Stock Price Up 9.8%What's Next? - MarketBeat
Alumis Inc stock (ALMS) jumps again on Nasdaq — here’s what’s driving the move and what comes next - TechStock²
Why Alumis Inc. Stock Is Suddenly Powering Higher - TipRanks
Chardan highlights Alumis’s (ALMS) potential after envudeucitinib hits all phase 3 endpoints in psoriasis trials - MSN
Top Small Cap Stocks To Watch NowJanuary 6th - MarketBeat
Chardan Highlights Alumis's (ALMS) Potential After Envudeucitinib Hits All Phase 3 Endpoints in Psoriasis Trials - Finviz
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):